2-(2,4-dioxo-1-pentyl-1,2-dihydroquinazolin-3(4H)-yl)-N-isopropylacetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-(2,4-dioxo-1-pentyl-1,2-dihydroquinazolin-3(4H)-yl)-N-isopropylacetamide
• 英文别名: 2-(2,4-dioxo-1-n-pentyl-1,2-dihydroquinazolin-3(4H)-yl)-N-isopropylacetamide；2-(2,4-dioxo-1-pentylquinazolin-3-yl)-N-propan-2-ylacetamide
• 化学式: C₁₈H₂₅N₃O₃
• 分子量: 331.415
• InChiKey: WZZUQXLSSQEAOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  69.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  邻氨基苯甲酸 在 potassium carbonate 、 potassium iodide 作用下， 以 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 25.5h， 生成 2-(2,4-dioxo-1-pentyl-1,2-dihydroquinazolin-3(4H)-yl)-N-isopropylacetamide
  参考文献：
  名称：

  Development of Quinazoline/Pyrimidine-2,4(1H,3H)-diones as Agonists of Cannabinoid Receptor Type 2

  摘要：

  Starting from a prototypical structure 1, we describe our efforts to design and obtain novel quinazoline/ pyrimidine-2,4(1H,3H)-diones with high CB2 agonist potency and selectivity as well as improved physicochemical characteristics, mainly hydrophilicity. The most potent and selective CB2 agonists, 8 and 36, in this series were also endowed with lower logP values than that of GW842166X and lead compound 1. These derivatives appear to be promising lead compounds for the development of future CB2 agonists.

  DOI：

  10.1021/acsmedchemlett.7b00007

文献信息

• Development of Quinazoline/Pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-diones as Agonists of Cannabinoid Receptor Type 2
  作者：Hai-Yan Qian、Zhi-Long Wang、You-Lu Pan、Li-Li Chen、Xin Xie、Jian-Zhong Chen

  DOI：10.1021/acsmedchemlett.7b00007

  日期：2017.6.8

  Starting from a prototypical structure 1, we describe our efforts to design and obtain novel quinazoline/ pyrimidine-2,4(1H,3H)-diones with high CB2 agonist potency and selectivity as well as improved physicochemical characteristics, mainly hydrophilicity. The most potent and selective CB2 agonists, 8 and 36, in this series were also endowed with lower logP values than that of GW842166X and lead compound 1. These derivatives appear to be promising lead compounds for the development of future CB2 agonists.